| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_035e00a382de34afa77ab7488ecc7486 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2020-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18ead0d34084ccdfcf327ba795ada36e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2bbe53ee6c459d316ecfdb0754788439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1aac00bba58abf8b5fdc5fccf2f18e06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6d39ef4d6f834b6142447b89a3b857c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03b8ff28d9ab6cc53fc439bbfc94e58a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_097d2c13a8051f068327e248033ede4a |
| publicationDate |
2020-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-111518799-A |
| titleOfInvention |
Construction of a pET44a-scFv1956# expression vector and its primers and applications |
| abstract |
The invention relates to the field of antibodies, in particular to the construction of a pET44a-scFv1956# expression vector, primers and applications thereof. The sequences of the primers are: primer 1 (44a up): 5'-TC CCC CGG GGC AGC CAG GTC CAA TTT GTA G-3'; primer 2 (44a down): 5'-CCG CTC GAG TTA ATT CAG ATC CTC TTC T‑3'. The construction method of the pET44a-scFv1956# expression vector of the present invention can smoothly construct the expression vector. The pET44a-scFv1956# of the present invention is composed of an antibody heavy chain variable region (VH)-connecting chain (G4S1) 3-light chain variable region (VL), and is a monovalent antibody without an Fc segment. It can solve the technical problem that the existing treatment methods are easy to cause the immune damage of the neuromuscular junction caused by the activation of the complement system. Since the pET44a‑scFv1956# expression vector can be beneficial to the antibody that inhibits the acetylcholine receptor, it can be used to prepare anti-wrinkle drugs and has a good therapeutic effect on wrinkles. |
| priorityDate |
2020-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |